Company Overview - Dongfang Ocean (SZ 002086) announced that its wholly-owned subsidiary, Aiveke Biotechnology, has received registration approval from the Shandong Provincial Drug Administration for its procalcitonin (PCT) testing kit, which is now a registered medical device [1] - As of the latest report, Dongfang Ocean has a market capitalization of 4.7 billion yuan [1] Revenue Composition - For the first half of 2025, Dongfang Ocean's revenue composition is as follows: - Aquaculture processing accounts for 73.14% - In-vitro diagnostics account for 10.19% - Marine aquaculture accounts for 9.97% - Other businesses, including leasing and others, account for 6.7% [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Aiveke Biotechnology Co., Ltd., has received a medical device registration certificate from the Shandong Provincial Drug Administration for its self-developed procalcitonin (PCT) assay kit, which is approved for market launch [1] Group 1 - The PCT assay kit is designed for the quantitative detection of procalcitonin levels in human serum, plasma, and whole blood samples [1] - The product has not yet been put into production, and its actual sales will be influenced by market expansion efforts and actual market demand [1] - The impact of Aiveke Biotechnology Co., Ltd. on the company's performance this year has been minimal, and future impacts remain uncertain [1]

证券代码：002086 证券简称：东方海洋 公告编号：2025-068 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的降钙素原（PCT）测定试剂盒（荧光免疫层析法）于近 日取得了山东省药品监督管理局的注册批准，获得医疗器械注册证，具体情况如 下： 一、产品信息 | 产品名称 | 降钙素原（PCT）测定试剂盒（荧光免疫层析法） | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 注册证编号 | 鲁械注准 20252400747 | | | | | | | | 注册人名称 | 艾维可生物科技有限公司 | | | | | | | | 注册证有效期 | 年 月 日 2025 11 10 | 12 | 月 | 日至 | 2030 | 12 | 年 | | 适用范围 | 用于体外定量检测人血清、血浆、全血样本中的降钙素 ...

Core Insights - The article discusses the development status and investment strategies of China's deep-sea technology industry, highlighting the competitive landscape and key players in the sector [1][6]. Company Overview - Major listed companies in the deep-sea technology sector include China Shipbuilding (600150.SH), China National Offshore Oil Corporation (601808.SH), and Zhenhua Heavy Industries (600320.SH), among others [1][2]. - These companies cover a wide range of areas including high-end equipment manufacturing, oil and gas exploration services, and underwater communication and detection [1][6]. Financial Performance - In the first three quarters of 2025, China Shipbuilding led the sector with over 100 billion RMB in revenue, although it faced low overall gross margins of 12.6% [5][13]. - Companies like China Haifang and ShenKai Co. demonstrated high gross margins exceeding 35%, indicating strong technical barriers in their niche markets [5][13]. - The financial metrics reveal that many companies have ROE (Return on Equity) concentrated around 3%-4%, while some, like Juyi Rigging and China Haifang, reported ROE below 2% [10][13]. Business Strategies - Companies are focusing on integrating advanced technologies such as AI, big data, and smart manufacturing into their operations [15][17]. - Leading firms are accelerating the intelligent upgrade and green transformation of deep-sea equipment, while smaller companies are innovating in underwater robotics and new marine materials [15][17]. Regional and Global Expansion - Most companies are strategically positioned along China's coast and are expanding their reach globally, particularly in Southeast Asia, Europe, and the Americas [6][7]. - This regional layout aligns with national strategies for marine power and international industrial development [6][7]. Future Development Plans - Companies are planning to invest in new technologies and expand their product lines, focusing on sustainable practices and international market penetration [16][17]. - For instance, China Shipbuilding aims to enhance its market share through mergers and acquisitions, while Zhongtian Technology is expanding its global footprint in submarine cable and marine communication systems [16][17].

Group 1 - The core point of the article is that Shandong Oriental Ocean Technology Co., Ltd. has received registration approval from the Shandong Provincial Drug Administration for its self-developed methotrexate testing reagent, which utilizes liquid chromatography-tandem mass spectrometry [2] Group 2 - The approved product is a medical device, indicating a significant advancement in the company's product offerings in the biotechnology sector [2] - The approval highlights the company's commitment to innovation and development in the field of medical testing [2]

证券代码：002086 证券简称：东方海洋 公告编号：2025-067 | 产品名称 | 甲氨蝶呤检测试剂（液相色谱-串联质谱法） | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 注册证编号 | 鲁械注准 20252400746 | | | | | | | | | 注册人名称 | 质谱生物科技有限公司 | | | | | | | | | 注册证有效期 | 月 月 2025 12 11 | 年 | 年 | 12 | 日 | 日至 | 2030 | 10 | | 适用范围 | 用于体外定量检测人体血清或血浆中甲氨蝶呤的含量。 | | | | | | | | 山东东方海洋科技股份有限公司 关于子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 质谱生物科技有限公司今年对公司的业绩影响较小，本次获批上市的甲 氨蝶呤检测试剂（液相色谱-串联质谱法）的投产及对公司业绩的后续影响具有 不确定性，请广大投资者注意投资风险。 2. ...

产品名称：甲氨蝶呤检测试剂（液相色谱-串联质谱法），注册证编号：鲁械注准 20252400746，适用 范围：用于体外定量检测人体血清或血浆中甲氨蝶呤的含量。 格隆汇12月15日丨东方海洋(002086.SZ)公布，公司子公司质谱生物科技有限公司自主研发的甲氨蝶呤 检测试剂(液相色谱-串联质谱法)于近日取得了山东省药品监督管理局的注册批准，获得医疗器械注册 证。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002086 证券简称：东方海洋 公告编号：2025-066 山东东方海洋科技股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第1号一一主板上市公司规范运作》等法律、行政法规、部门规章、规 范性文件及《公司章程》的有关规定。 4、会议时间： （4）根据相关法规应当出席股东会的其他人员。 （1）现场会议时间：2025年12月26日09:30 8、会议地点：山东省烟台市莱山区澳柯玛大街18号公司会议室。 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2025年12月26日9:15-9:25， 9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2025年12月26日9:15 至 ...

每经头条（nbdtoutiao）——最新1520元，飞天茅台批价两年跌了43%，经销商躺赢神话破灭，当潮水 退去谁在裸泳？ 每经AI快讯，东方海洋（SZ 002086，最新价：2.5元）12月10日午间发布公告称，公司第八届第二十六 次董事会会议于2025年12月10日以通讯表决方式召开。会议审议了《关于召开公司2025年第二次临时股 东会的议案》等文件。 （记者 王晓波） 2025年1至6月份，东方海洋的营业收入构成为：水产加工业占比73.14%，体外诊断占比10.19%，海水 养殖业占比9.97%，其他业务--租赁及其他占比6.7%。 ...

上市公司独立董事候选人声明与承诺 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办 法》和深圳证券交易所业务规则规定的独立董事任职资格 和条件。 ☑ 是 □ 否 如否，请详细说明：______________________________ 声明人张中华作为山东东方海洋科技股份有限公司第 八届董事会独立董事候选人，已充分了解并同意由提名人 烟台市正大城市建设发展有限公司提名为山东东方海洋科 技股份有限公司（以下简称该公司）第八届董事会独立董 事候选人。现公开声明和保证，本人与该公司之间不存在 任何影响本人独立性的关系，且符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立 董事候选人任职资格及独立性的要求，具体声明并承诺如 下事项： 一、本人已经通过山东东方海洋科技股份有限公司第 八届董事会提名委员会或者独立董事专门会议资格审查， 提名人与本人不存在利害关系或者其他可能影响独立履职 情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：_____________________________ 二、本人不存在《 ...